54 results about "Inflammatory pain" patented technology

The present invention relates to a voltage-gated sodium channel Nav1.8 selective inhibitor and the use thereof in the preparation of a related drug. The drug is used for treating diseases responsive to the inhibition of voltage-gated sodium channel NaV1.8, such as chronic pain, enterodynia, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, post-operative pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough or arrhythmia. Specifically, the present invention relates to a compound as shown in formula (X), and an isomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof.

The application discloses application of hen egg white lysozyme (HEL) in relieving chronic pain, and experiment results show that HEL significantly and selectively relieves inflammatory pain, neuropathic pain and static mechanical allodynia induced by chemotherapy pain. Meanwhile, experiments show that HEL causes the expression of a mechanical sensitivity ion channel TACAN in the PRKN / TACAN pathway on the cell membrane to be reduced by up-regulating the expression of PRKN protein of primary sensory neurons in the dorsal root ganglion, thereby significantly inhibiting static mechanical allodynia. The application firstly finds that HEL has the effect of relieving static mechanical allodynia and a deep mechanism, and the source of HEL is non-toxic and safe, and has potential application value in preparation of medicines for preventing, treating and relieving chronic pain, and has great clinical significance.

This disclosure presents systems and methods for baroreflex activation therapy (BAT) to regulate inflammation by modulating autonomic nervous system activity. Electrical stimulation is delivered to one or more baroreceptors, and real-time physiological signals are monitored, including inflammatory biomarkers (e.g., TNF-α, IFN-γ, IL-1, IL-6, IL-12, CRP) and autonomic parameters such as heart rate variability (HRV). A closed-loop feedback module analyzes biomarker fluctuations and autonomic balance changes and dynamically modifies stimulation parameters, including amplitude, pulse width, frequency, and duty cycle, to suppress systemic inflammation and restore autonomic balance. In certain embodiments, multi-channel stimulation architectures and AI-driven algorithms or machine learning models analyze biomarker trends and historical patient response patterns to optimize therapy. The disclosed BAT systems and methods may be used to treat inflammatory diseases, autoimmune disorders, cancer progression, chronic inflammatory pain conditions, arrhythmias associated with inflammation, and metabolic dysfunction.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The invention relates to an application of a halophenol compound 2, 4 ', 5'-trihydroxy-5, 2 '-dibromo benzophenone in preparation of an analgesic drug. Experiments prove that the compound has a definite analgesic effect, can significantly inhibit mouse writhing reaction induced by acetic acid and II-phase inflammatory pain induced by formalin, and prolongs the thermal stimulation tail retraction incubation period, and the effect is superior to that of aspirin. Furthermore, in a nitroglycerin-induced migraine rat model, the compound can effectively improve behavioral symptoms and brain tissue pathological damage and remarkably regulate key index levels of CGRP, PGE2, ET-1, IL-1beta, IL-6, TNF-alpha, 5-HT and the like in plasma, which shows that the compound can be applied to preparation of analgesic drugs, preparation of drugs for treating migraine, preparation of drugs for treating migraine and the like. The invention particularly has important application value in medicines for preventing and / or treating migraine.

The utility model discloses a double-foot balance pain measurement test mouse cage which comprises a bottom plate, a base plate is fixedly connected to the bottom plate, two flat pedals are symmetrically arranged on the upper surface of the base plate, and pressure sensors are arranged between the two flat pedals and the base plate respectively. Two vertical plates are symmetrically fixed to the upper surface of the bottom plate and used for supporting the left foot and the right foot of a mouse respectively, an inclined pedal is fixed between the two vertical plates and used for supporting the front foot of the mouse, the opposite faces of the two vertical plates are each provided with a baffle, and a plurality of guide columns are fixed to the side wall of each baffle. By means of the two flat pedals symmetrically arranged on the bottom plate and the base plate, standing support is provided for a mouse, the built-in pressure sensors can monitor and record pressure distribution of the rear feet of the mouse in real time, and therefore the inflammatory pain state of the rear feet of the mouse can be accurately reflected, and the mouse can be conveniently taken out. And the accuracy of experimental data is improved.

The present invention relates to a sulfonylurea derivative and medical uses thereof, specifically relating to the sulfonylurea derivative shown in general formula (I), a preparation method thereof, a pharmaceutical composition containing same, and a use of same for treating diseases and disorders affected by neuronal damage, for example: cerebral stroke, brain damage, neuropathic pain, migraines, inflammatory pain, chronic pain, or depression. The definition of each group in the general formula (I) is the same as that in the description.

This invention discloses the application of a polypeptide in inhibiting inflammatory pain, belonging to the field of biomedicine. The polypeptide is Mexneurin-3 (Mx-3), one of three Mexneurin polypeptides formed by the cleavage of ProMexneurin, a protein precursor found in the mammalian central nervous system, by proprotein convertase. This invention reveals that Mx-3, as an endogenous polypeptide, has significant analgesic effects, inhibiting both acute and chronic inflammatory pain with fewer side effects and greater safety. This invention also elucidates the analgesic mechanism of Mx-3, finding that it upregulates diacylglycerol (DAG) levels in the spinal cord and activates protein kinase C (PKC). The application of Mx-3 in inhibiting inflammatory pain provided by this invention can be used to develop safer and more effective novel analgesics, providing new ideas and references for the treatment of inflammatory pain.

The inventor has synthesized 2 '-O > 2-methoxyethyl modified FXYD2-LASO (FXYD2-LASO-gapmer) and injects the 2'-O > 2-methoxyethyl modified FXYD2-LASO and the 2 '-O > 2-methoxyethyl modified FXYD2-LASO-gapmer into the vein, and an application way with relatively small invasiveness is provided. Intravenous administration of the FXYD2 optimized antisense oligonucleotide (LASO) with MOE, compared to intrathecal administration, allows for a long-term effect on pain. The inventors have proven this long term effect on neuropathic pain in spinal nerve ligation (SNL) rat models and inflammatory pain in complete Freund's adjuvant (CFA) induced rat models. Thus, the present invention relates to antisense oligonucleotides targeting FXYD2 for use in the treatment of pain wherein the antisense oligonucleotides are administered intravenously.

The present invention relates to a morphinan-type compound, a preparation method therefor, a composition thereof and the use thereof. Specifically disclosed is a compound I or a pharmaceutically acceptable salt thereof. The morphinan-type compound of the present invention has one or more of the following effect advantages: (1) a relatively high binding affinity for an opioid receptor; (2) a significant agonistic effect on KOR and MOR; (3) good selectivity for a κ receptor; and (4) a good therapeutic effect on inflammatory pain (for example, rapid onset of action or significant analgesic effect).

A transdermal patch for delivering lidocaine for pain relief comprises a backing layer, an adhesive layer, and a composition containing lidocaine in an amount ranging from about 1% to about 10% by weight and heparin as a non-anticoagulant permeation enhancer in an amount ranging from about 1% to about 50% by weight. The heparin enhances permeation of lidocaine through the skin without exerting systemic anticoagulant effects by temporarily disrupting lipid bilayers in the stratum corneum to create microchannels for increased diffusion of lidocaine molecules. The patch provides effective relief for multiple pain types including neuropathic pain, inflammatory pain, ischemic pain, post-surgical pain, nociplastic pain, mechanical pain, and compressive pain. The transdermal patch is configured to provide sustained release of lidocaine for periods ranging from about 8 hours to about 24 hours, reducing pain by at least 50% with minimal systemic absorption.

The present invention relates to a synergistic admixture of Gabapentin and Ketoprofen, preferably Ketoprofen Lysine, to a pharmaceutical composition comprising said admixtures and to the use of said admixtures or pharmaceutical compositions in the treatment of acute or chronic pain, in particular in the treatment of neuropathic or inflammatory pain.

The application relates to the technical field of pharmaceutical chemistry, and discloses a flurbiprofen ester enantiomer prodrug compound, a preparation method thereof, a pharmaceutical composition and purposes, the compound is (R)-AF377 or (S)-AF377, is formed by covalently connecting a carboxyl of (R)-flurbiprofen, (S)-flurbiprofen and a phenolic hydroxyl of acetaminophen through an ester bond, corresponding chiral carbons are R configuration and S configuration respectively, and structures are shown in formula (I) and formula (II). The application further provides a preparation method of the compound, a pharmaceutical composition containing the compound and purposes of the compound in pain, inflammation or fever treatment. The compound has high optical purity, releases an active ingredient in the liver, (S)-AF377 has synergistic anti-inflammatory analgesic activity, (R)-AF377 has independent analgesic activity, can reduce side effects of single drug use, improves bioavailability, and provides a new drug selection for treatment of mild to moderate inflammatory pain.

Disclosed herein are methods and compositions for treating a disease or disorder in a subject in need thereof. The methods may include administering to the subject a therapeutically effective amount of a GPR37 agonist. The disease or disorder may be selected from inflammation, inflammatory pain, chronic pain, viral infection, bacterial infection, malaria, sepsis, or a combination thereof.

The invention belongs to the technical field of biological medicine, and particularly relates to synthesis and application of an oligopeptide compound. According to the invention, a plurality of methods are adopted to carry out structure optimization on WvVf-OCH3, and a series of WvVf-OCH3 structural optimization mutants with a relatively good inhibition effect on nAChRs are obtained. The mutant has excellent performance in the aspects of safety, stability and in-vivo efficacy, and has definite efficacy and development potential in the aspects of relieving muscle tension, removing wrinkles and relieving inflammatory pain. The WvVf-OCH3 mutant can be used as a candidate medicine for treating symptoms such as muscle tension, spasm and pain, or can be used as an active raw material of a medical beauty product with a wrinkle removing function.

Disclosed is a composition for preventing, ameliorating or treating arthritis, which contains a hydrangea crassifolia extract or hydrangeol as an active ingredient. The present invention not only inhibits the expression of MMP-1 and MMP-9, increases the synthesis of type II procollagen, and alleviates inflammation, but also has an effect of preventing, ameliorating or treating arthritis by inhibiting inflammatory pain.

The invention relates to application of anacycline A in preparation of analgesic drugs, in particular to an anacycline A compound separated from anacycline roots. The compound can be applied to analgesic drugs with inhibition effects on transient receptor potential cation channel subfamily M member 8 (TRPM8), a voltage-gated potassium ion channel 1.2 (Kv1.2), a voltage-gated potassium ion channel 1.3 (Kv1.3), transient receptor potential cation channel protein 6 (TRPC6) and a voltage-gated calcium ion channel 2.1 (Cav2.1), in particular to drugs for neuropathic pain, traumatic pain or inflammatory pain. The compound anacycline A can be combined with a plurality of analgesia-related targets, so that a synergistic effect is generated, the treatment effect is enhanced, and meanwhile, side effects and drug resistance are reduced.

The application discloses an indolone compound and a pharmaceutical composition and application thereof, and has a molecular structure as follows: the indolone compound has double activities of analgesia and antioxidation, can be used as an analgesic with an antioxidation function, and has application potential in inflammatory pain care.

The invention relates to the technical field of medicines, and particularly discloses application of 9-anthraformic acid in preparation of a non-addictive peripheral analgesic medicine. It is proved for the first time that 9-anthracene formic acid has a remarkable analgesic effect and can effectively relieve inflammatory pain, the action target is a peripheral part, central side effects such as addiction and respiratory depression of traditional opioid analgesic are avoided, gastrointestinal injury, cardiovascular risk and curative effect capping effect of non-steroidal anti-inflammatory drugs are also overcome, and the 9-anthracene formic acid can be applied to preparation of anti-inflammatory drugs. Animal experiments prove that the analgesic effect of the compound is comparable with that of classical opioid drug morphine, and a brand new candidate drug and an application direction are provided for developing novel non-addiction analgesic drugs.

The application provides a kind of cartilage polypeptide composition and its preparation method, the cartilage polypeptide 30-45%, auxiliary agent 10-25%, growth agent 3-8%, slow-release agent 2-9%, the balance is water, the application will cartilage polypeptide, auxiliary agent, growth agent and slow-release agent several ingredients scientific compatibility, preparation has the composition of protecting cartilage tissue, anti-inflammatory pain, effectively increase bone density effect, improve synovial tissue, there is no rebound ineffective condition after drug withdrawal.

The present application relates to the use of substituted indazoles for treatment and / or prophylaxis of allergic and / or inflammatory diseases in animals, especially for treatment and / or prophylaxis of atopic dermatitis, Flea Allergy Dermatitis, inflammatory bowel disease, osteoarthritis and inflammatory pain, non-infectious recurrent airway disease, insect hypersensitivity, asthma, respiratory disease, mastitis and endometritis in animals.

The present application relates to the use of substituted indazoles for treatment and / or prophylaxis of allergic and / or inflammatory diseases in animals, especially for treatment and / or prophylaxis of atopic dermatitis, Flea Allergy Dermatitis, inflammatory bowel disease, osteoarthritis and inflammatory pain, non-infectious recurrent airway disease, insect hypersensitivity, asthma, respiratory disease, mastitis and endometritis in animals.

The application relates to the technical field of medicines, and particularly discloses a class of celecoxib derivatives, a preparation method and application thereof. The derivative is formed by connecting celecoxib and straight-chain amino acids through a chemical bond, and the straight-chain amino acids are glycine, gamma-aminobutyric acid and the like. The derivative or a pharmaceutically acceptable salt and a pharmaceutical composition thereof can be used for preparing medicines for preventing and / or treating pain or nervous system diseases. The derivative has excellent water solubility, strong COX-2 inhibitory activity, good analgesic activity and anti-inflammatory activity, has good analgesic effects on inflammatory pain, neuropathic pain and visceral pain and the like, and has a wide application prospect.

The application discloses application of anterior piriform cortex GABAergic neurons as an analgesic target point, and relates to the technical field of neuroscience and pain. GABA The application discloses that the neural loop (APC GABA →MD) from the anterior piriform cortex GABAergic neurons to the thalamic dorsal medial nucleus plays a key role in pain regulation. Experiments prove that the loop can not only relieve acute pain, but also has a significant analgesic effect on the clinical treatment of intractable chronic inflammatory pain and neuropathic pain models, and shows a wide treatment application prospect.

The invention discloses a compound which is characterized in that the molecular structure of the compound is as follows: the compound can effectively inhibit COX-2 activity and scavenge free radicals at a micromolar concentration level, has anti-inflammatory, anti-oxidation and analgesic effects, and can be used as a nursing agent for inflammatory pain.

The application discloses a painkilling preparation containing radix scophulariae and radix aconiti and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine. The preparation is a transdermal patch, which is composed of a backing layer, a drug depot layer and an anti-sticking layer. The drug depot layer contains traditional Chinese medicine active ingredients and patch auxiliaries such as pressure-sensitive adhesive and transdermal absorption accelerators. The traditional Chinese medicine active ingredients take radix scophulariae and radix aconiti as the core drug pair, and are supplemented with one or more of the following drugs: qi-regulating analgesic drugs, blood-removing qi-regulating drugs, blood-activating analgesic drugs, blood-stasis-removing analgesic drugs, warm-qi-activating cold-dispelling drugs, wind-dispelling cold-dispelling drugs and external analgesic drugs. The application is a modern traditional Chinese medicine external preparation prepared by a patch technology, and the drug can penetrate the skin and directly reach the lesion, thereby playing a therapeutic role on inflammatory pain, cancer pain and idiopathic pain. The preparation has the characteristics of large drug loading, good transdermal absorption, fast analgesic effect, long-acting effect and avoidance of oral toxicity risk.

The application discloses a kind of customized analgesic hydrogel and its preparation and application.Specifically, the application discloses a new analgesic target, screens suitable drugs, and according to the characteristics of drug molecules, two-step method is customized to obtain sustained-release analgesic hydrogel.The two-step method is specifically divided into the following: first, according to the structure of drug molecules, aldehyde-based hyaluronic acid is synthesized to realize chemical drug loading;Second, adjust the concentration of Schiff base to form a double grid environment to realize injectability.Load the inhibitory drug TAPI-1 for the new target ADAM17 of stomatognathic inflammatory pain, construct a drug delivery system with targeted delivery, sustained-release analgesia, local injection and long-acting effect.Compared with the prior art, the drug delivery system obtained by the application has excellent sustained-release performance, the prolonged drug release is consistent with the hyperalgesia window period of stomatognathic inflammatory pain, precise and effective pain management is achieved, and the operation is simple, and has good conversion application prospect.

The invention relates to a morphinan type compound as well as a preparation method, a composition and application thereof. Specifically disclosed is a compound I or a pharmaceutically acceptable salt thereof. The morphinan type compound provided by the invention has one or more of the following effects and advantages: (1) the morphinan type compound is relatively high in binding affinity with an opioid receptor; (2) the compound has an obvious agonistic effect on KOR and MOR; (3) the selectivity to a kappa receptor is good; and (4) the ointment has a good treatment effect on inflammatory pain (for example, the ointment takes effect quickly or has an obvious pain effect).

The present invention relates to an inhibitor of FXYD2 wherein the inhibitor reduces the expression and / or activity of FXYD2 in a subject in need thereof and targets at least a region comprising or consisting of nucleotides 219-229 of SEQ ID NO: 3. The inventors have demonstrated that targeted FXYD2 regions can be used to inhibit and / or reduce the expression and / or activity of FXYD2. The antisense oligonucleotide (SEQ ID NO: 4) targeting the FXYD2 genes of the rat and the human is designed and synthesized by the FXYD2 genes of the rat and the human. They have been subjected to an intrathecal injection of FXYD2 optimized ASO in two modes of rat pain (neuropathic pain and inflammatory pain). It has been proved that FXYD2 ASO can effectively reduce the expression of FXYD2 ASO in rat dorsal root ganglion (DRG). It has been proved that the FXYD2 ASO can significantly reduce the neuropathic pain in a spinal nerve ligation (SNL) rat model, and the analgesic effect of the FXYD2 ASO on the neuropathic pain is better than that of the leading Zconotide in the current market. The FXYD2 ASO also shows that the FXYD2 ASO can obviously reduce the inflammatory pain in a rat model induced by a complete Freund's adjuvant (CFA).

This invention is in the field of medicinal chemistry. In particular, the invention relates to anew class of small-molecules having a piperazine or piperidine structure which function as either inhibitors of pan-T-type calcium channel activity (e.g., CaV3.1 voltage gated calcium channel activity) (e.g., CaV3.2 voltage gated calcium channel activity) (e.g., CaV3.3 voltage gated calcium channel activity) (e.g., depolarization-induced calcium influx) or specific inhibitors of CaV3.2 voltage gated calcium channel activity, and their use as therapeutics for the treatment and / or prevention of pan-T-type calcium channel related pain (e.g., CaV3.1 related pain) (e.g., CaV3.2 related pain) (e.g., CaV3.3 related pain) (e.g., HIV-associated peripheral sensory neuropathy, chemotherapy-induced peripheral neuropathy (CIPN), spinal nerve ligation (SNL) induced neuropathy) (e.g., tonic, neuropathic, and / or inflammatory pain) and related conditions.